ly 274614 has been researched along with midazolam in 1 studies
Studies (ly 274614) | Trials (ly 274614) | Recent Studies (post-2010) (ly 274614) | Studies (midazolam) | Trials (midazolam) | Recent Studies (post-2010) (midazolam) |
---|---|---|---|---|---|
96 | 0 | 15 | 9,834 | 3,191 | 3,301 |
Protein | Taxonomy | ly 274614 (IC50) | midazolam (IC50) |
---|---|---|---|
Cytochrome P450 3A4 | Homo sapiens (human) | 2.7427 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bartlett, SE; Cramond, T; Smith, MT | 1 |
1 other study(ies) available for ly 274614 and midazolam
Article | Year |
---|---|
The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex.
Topics: Akathisia, Drug-Induced; Animals; Behavior, Animal; Binding Sites; Dose-Response Relationship, Drug; Injections, Intraventricular; Isoquinolines; Male; Midazolam; Morphine Derivatives; Rats; Rats, Sprague-Dawley; Receptors, GABA; Receptors, N-Methyl-D-Aspartate; Specific Pathogen-Free Organisms | 1994 |